General Medicine
Lymphadenopathy Workup
Distinguish localised vs generalised, reactive vs malignant; targeted investigations + biopsy red flag features.
Source: NICE NG12; BMJ Best Practice
Step 1 of ~5
info
Initial Assessment
Lymphadenopathy: enlarged lymph nodes (>1 cm typically; >2 cm supraclavicular always abnormal).
Characterise:
• Site: cervical (most common), supraclavicular (always pathological), axillary, inguinal, mediastinal, abdominal.
• Size, consistency (soft/firm/hard/rubbery), tenderness, mobility / fixed, overlying skin.
• Distribution: localised vs generalised (≥2 non-contiguous regions).
• Duration: acute (<2 weeks usually reactive); chronic (>2 weeks → investigate).
Red flags:
• Hard, fixed, non-tender → malignancy.
• Supraclavicular (Virchow's = abdominal malignancy; Troisier's sign).
• Generalised + B symptoms (fever, night sweats, weight loss).
• Persistent >3–4 weeks.
• Associated organomegaly.
• Older age.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Inclisiran · PCSK9-targeted siRNA
- Apremilast · Targeted Synthetic DMARD — Phosphodiesterase-4 (PDE4) Inhibitor
- Filgotinib · Targeted Synthetic DMARD — Selective JAK1 Inhibitor
- Lutetium-177 PSMA-617 · PSMA-Targeted Radioligand Therapy
- Sunitinib · Multi-Targeted Receptor Tyrosine Kinase Inhibitor (VEGFR, PDGFR, KIT)
- Cabozantinib · Multi-Targeted TKI (VEGFR2, MET, AXL, RET)
Pathways
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Unintentional Weight Loss Workup · NICE NG12; BSG
- Chronic Fatigue Workup · NICE NG206; BMJ Best Practice
- Pre-op Medical Clearance · NICE NG45; ESC 2022
- Secondary Hypertension Workup · NICE NG136; ESH 2023
- Splenomegaly Workup · BSH; BMJ Best Practice
Decision support only. Always apply local guidelines and clinical judgement.